New insider activity at Guardant Health ( (GH) ) has taken place on January 9, 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Chief People Officer Terilyn J. Monroe has sold 10,031 shares of Guardant Health stock in a transaction valued at $1,124,235, signaling a notable insider move that may draw attention from investors tracking executive trading activity.
Recent Updates on GH stock
Over the last day, Guardant Health has seen a cluster of bullish analyst revisions to their valuation models, reflecting growing optimism about the company’s medium‑term fundamentals rather than any single new headline or earnings release. Stifel cited expectations for 2026, highlighting anticipated growth in testing volumes and average selling prices, along with upcoming publication and reimbursement milestones that could support broader adoption of Guardant’s assays and sustain investor interest. TD Cowen’s adjustment came as part of a broader Q4 diagnostics sector preview, where the firm expects solid upcoming results and a constructive 2026 outlook, emphasizing that underlying sector fundamentals remain strong. Mizuho’s change was driven by an across‑the‑board update to its medical devices and diagnostics models, indicating a refreshed view of the space that is favorable to Guardant. Guggenheim’s revision followed meetings with management and subsequent updates to its financial models and forecasts across its Diagnostics and Life Sciences Tools coverage, suggesting improved confidence in Guardant’s trajectory based on direct company commentary. A BTIG‑hosted virtual meeting with Guardant’s management is also on the calendar, which may further inform investor sentiment, but the primary driver of recent moves has been these model‑based upgrades rooted in better volume, pricing, and sector outlook assumptions rather than any noted abrupt change in market conditions or a specific new company announcement.
Spark’s Take on GH Stock
According to Spark, TipRanks’ AI Analyst, GH is a Neutral.
Guardant Health’s strong technical momentum and positive earnings call insights are offset by financial instability and valuation concerns. Strategic partnerships and recent corporate events provide a supportive backdrop for future growth, but profitability and financial health remain critical areas for improvement.
To see Spark’s full report on GH stock, click here.
More about Guardant Health
YTD Price Performance: 6.46%
Average Trading Volume: 2,541,630
Technical Sentiment Signal: Buy
Current Market Cap: $14.22B